文献速递产科母胎医学

迈向产科疾病新分类:依据胎盘病理分类可改善母血生物标志物对重大产科综合征的预测性能

Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology.
PubMed 文献 · Am J Obstet Gynecol · 2022-09-03

本研究基于4006名孕妇的前瞻性母队列,回顾性分析1499例,按胎盘母体血管灌注不良病变的有无对产科综合征分类,评估胎盘生长因子(PlGF)、可溶性fms样酪氨酸激酶-1(sFlt-1)及PlGF/sFlt-1比值纵向变化。结果显示按胎盘病理分类后,生物标志物异常与产科综合征的关联强度增强,且差异出现更早。

要点

  • 按胎盘母体血管灌注不良病变有无分类,PlGF、sFlt-1及比值差异出现更早。
  • 有病变时PlGF/sFlt-1比值异常与子痫前期关联aOR 13.6 vs 无病变6.7。
  • 有病变时比值异常与小于胎龄儿关联aOR 8.1 vs 无病变4.4。

核心结论

  • 按胎盘母体血管灌注不良病变有无对产科综合征分类,可使生物标志物在更早孕期具有信息价值,并增强生物标志物与临床结局的关联强度。
  • 作者提出基于胎盘病理的新分类法将有助于生物标志物的发现、应用及这些疾病的预测和预防。

研究设计与样本

  • 回顾性病例队列研究,基于前瞻性纳入的4006名孕妇的母队列。
  • 病例队列共1499名孕妇,包括从母队列随机选取的1000名患者及母队列中所有产科综合征患者。
  • 孕妇分为六组:无妊娠并发症的足月分娩(n=540,对照)、早产临产和分娩(n=203)、未足月胎膜早破(n=112)、子痫前期(n=230)、小于胎龄儿(n=334)及其他妊娠并发症(n=182)。
  • 采用酶联免疫吸附试验测定7560份纵向样本中的母体血浆PlGF和sFlt-1浓度。
  • 胎盘病理学家在不知临床结局的情况下诊断胎盘母体血管灌注不良病变的有无。

主要发现

  • 按胎盘母体血管灌注不良病变有无分类时,病例与对照间PlGF、sFlt-1及PlGF/sFlt-1比值的平均血浆浓度差异在孕期更早出现。
  • 有胎盘母体血管灌注不良病变时,异常PlGF/sFlt-1比值与产科综合征的关联强度增加:子痫前期aOR 13.6 vs 6.7;小于胎龄儿aOR 8.1 vs 4.4;未足月胎膜早破aOR 5.5 vs 2.1;早产aOR 3.3 vs 2.1(所有P<0.05)。
  • 孕28至32周时,后续因早产临产伴完整胎膜分娩及未足月胎膜早破的患者中,若两组均有胎盘母体血管灌注不良病变,则PlGF/sFlt-1比值异常;无胎盘病变者该关联不显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The major challenge for obstetrics is the prediction and prevention of the great obstetrical syndromes. We propose that defining obstetrical diseases by the combination of clinical presentation and disease mechanisms as inferred by placental pathology will aid in the discovery of biomarkers and add specificity to those already known. OBJECTIVE: To describe the longitudinal profile of placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), and the PlGF/sFlt-1 ratio throughout gestation, and to determine whether the association between abnormal biomarker profiles and obstetrical syndromes is strengthened by information derived from placental examination, eg, the presence or absence of placental lesions of maternal vascular malperfusion. STUDY DESIGN: This retrospective case cohort study was based on a parent cohort of 4006 pregnant women enrolled prospectively. The case cohort of 1499 pregnant women included 1000 randomly selected patients from the parent cohort and all additional patients with obstetrical syndromes from the parent cohort. Pregnant women were classified into six groups: 1) term delivery without pregnancy complications (n=540; control); 2) preterm labor and delivery (n=203); 3) preterm premature rupture of the membranes (n=112); 4) preeclampsia (n=230); 5) small-for-gestational-age neonate (n=334); and 6) other pregnancy complications (n=182). Maternal plasma concentrations of PlGF and sFlt-1 were determined by enzyme-linked immunosorbent assays in 7560 longitudinal samples. Placental pathologists, masked to clinical outcomes, diagnosed the presence or absence of placental lesions of maternal vascular malperfusion. Comparisons between mean biomarker concentrations in cases and controls were performed by utilizing longitudinal generalized additive models. Comparisons were made between controls and each obstetrical syndrome with and without subclassifying cases according to the presence or absence of placental lesions of maternal vascular malperfusion. RESULTS: 1) When obstetrical syndromes are classified based on the presence or absence of placental lesions of maternal vascular malperfusion, significant differences in the mean plasma concentrations of PlGF, sFlt-1, and the PlGF/sFlt-1 ratio between cases and controls emerge earlier in gestation; 2) the strength of association between an abnormal PlGF/sFlt-1 ratio and the occurrence of obstetrical syndromes increases when placental lesions of maternal vascular malperfusion are present (adjusted odds ratio [aOR], 13.6 vs 6.7 for preeclampsia; aOR, 8.1 vs 4.4 for small-for-gestational-age neonates; aOR, 5.5 vs 2.1 for preterm premature rupture of the membranes; and aOR, 3.3 vs 2.1 for preterm labor (all P<0.05); and 3) the PlGF/sFlt-1 ratio at 28 to 32 weeks of gestation is abnormal in patients who subsequently delivered due to preterm labor with intact membranes and in those with preterm premature rupture of the membranes if both groups have placental lesions of maternal vascular malperfusion. Such association is not significant in patients with these obstetrical syndromes who do not have placental lesions. CONCLUSION: Classification of obstetrical syndromes according to the presence or absence of placental lesions of maternal vascular malperfusion allows biomarkers to be informative earlier in gestation and enhances the strength of association between biomarkers and clinical outcomes. We propose that a new taxonomy of obstetrical disorders informed by placental pathology will facilitate the discovery and implementation of biomarkers as well as the prediction and prevention of such disorders.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Romero R, Jung E, Chaiworapongsa T, et al. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. Am J Obstet Gynecol. 2022. PMID: 36180175. doi:10.1016/j.ajog.2022.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。